SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Oct 2014 07:00

RNS Number : 8130T
Victrex PLC
09 October 2014
 



 

 

 

 

9 October 2014

 

Victrex plc - Pre-close trading statement

 

"A strong finish to 2014 - growth momentum continues"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its pre-close trading statement for the financial year ended 30 September 2014, ahead of its preliminary results on Tuesday 9 December 2014.

 

Victrex delivered a strong finish to 2014, with the Group continuing its volume growth momentum from the first half year across our strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Full year Group sales volume of 3,551 tonnes increased by 22% (2013: 2,920 tonnes), with second half year sales volume of 1,967 tonnes increasing by 29% on last year (H2 2013: 1,528 tonnes). Although sales volumes were particularly strong, our profit expectations remain largely unchanged.

 

The strong volume performance in our Victrex Polymer Solutions (VPS) business reflects core growth and higher than expected volumes in the second half year from Consumer Electronics. Stripping out sales volumes across the entire Electronics segment, second half year sales volume increased by 6% on the prior year. Our higher margin Speciality Products business, including Aptiv film, again performed well during the year. With continued growth in Aptiv, we will bring an additional production line on stream during the first half of our new financial year.

 

In our higher margin Invibio medical business, full year revenue increased by 5% to £53.4m (2013: £50.8m), reflecting steady improvement in the Spine market. The focus for 2015 remains the roll-out of new products into the Spine market, with regulatory applications lodged in the US and Europe for the innovative PEEK-OPTIMA® HA-Enhanced product, which enhances bone-on-growth. Pending regulatory approval, adoption and roll-out will commence during the first half.

 

As we start our new financial year, our growth momentum remains positive. Although currency headwinds remain considerable in 2015, our forthcoming new PEEK and Aptiv film capacity, technical excellence and marketing know-how keep us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead / Rebecca Hall +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the strategic markets of Aerospace, Automotive, Electronics, Energy and Medical. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Visit www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Thursday 9 October 08.30 UK time. For dial in details contact Rebecca Hall at Pendomer on +44 (0) 203 603 5220 or Rebecca.Hall@pendomer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGBAUUPCGCR
Date   Source Headline
30th Nov 20161:30 pmRNSTotal Voting Rights
17th Nov 20162:19 pmRNSDirector/PDMR Shareholding
10th Nov 201611:11 amRNSAdditional Listing
31st Oct 20162:39 pmRNSTotal Voting Rights
18th Oct 20162:10 pmRNSDirector/PDMR Shareholding
11th Oct 20167:00 amRNSTrading Statement
30th Sep 20161:11 pmRNSTotal Voting Rights
19th Sep 20164:28 pmRNSDirector/PDMR Shareholding
19th Sep 20163:18 pmRNSHolding(s) in Company
31st Aug 20169:28 amRNSTotal Voting Rights
17th Aug 20163:46 pmRNSDirector/PDMR Shareholding
29th Jul 20162:47 pmRNSTotal Voting Rights
28th Jul 20162:57 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSInterim Management Statement
19th Jul 20164:34 pmRNSDirector/PDMR Shareholding
30th Jun 201610:00 amRNSTotal Voting Rights
17th Jun 20163:56 pmRNSDirector/PDMR Shareholding
14th Jun 20164:42 pmRNSHolding(s) in Company
14th Jun 20164:24 pmRNSHolding(s) in Company
1st Jun 20169:02 amRNSBlock listing Interim Review
31st May 201611:42 amRNSTotal Voting Rights
26th May 20164:26 pmRNSHolding(s) in Company
17th May 20164:11 pmRNSDirector/PDMR Shareholding
16th May 20167:00 amRNSHalf-year Report
3rd May 20163:27 pmRNSHolding(s) in Company
3rd May 20163:15 pmRNSHolding(s) in Company
3rd May 20163:00 pmRNSHolding(s) in Company
29th Apr 201610:00 amRNSTotal Voting Rights
28th Apr 20167:00 amRNSResolution of US FTC inquiry
21st Apr 20167:00 amRNSDirector Declaration
19th Apr 201611:07 amRNSDirector/PDMR Shareholding
7th Apr 20167:00 amRNSTrading Statement
31st Mar 20162:51 pmRNSTotal Voting Rights
31st Mar 20161:45 pmRNSTotal Voting Rights
17th Mar 201610:15 amRNSDirector/PDMR Shareholding
1st Mar 20165:00 pmRNSDirector/PDMR Shareholding
29th Feb 20162:18 pmRNSTotal Voting Rights
26th Feb 20163:09 pmRNSHome Member State
17th Feb 201611:27 amRNSDirector/PDMR Shareholding
10th Feb 20163:55 pmRNSResult of AGM
10th Feb 20167:00 amRNSAGM Statement
9th Feb 20164:44 pmRNSHolding(s) in Company
5th Feb 20161:38 pmRNSGrant of Options
29th Jan 20169:27 amRNSTotal Voting Rights
19th Jan 201611:39 amRNSDirector/PDMR Shareholding
19th Jan 201610:08 amRNSDirector Declaration
5th Jan 201612:00 pmRNSAnnual Financial Report
31st Dec 201510:00 amRNSTotal Voting Rights
17th Dec 20154:23 pmRNSHolding(s) in Company
17th Dec 20153:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.